The executive staff of Cannabis Science are analyzing the near term implications of House Resolution 6187, introduced by Rep. James Himes (D-CT) and Rep. Barbara Lee (D-CA) on July 25, 2012 and referred to the Committee on Armed Services, and the Committee on Energy and Commerce. HR 6187 calls for a $100 million, 5-year appropriation to establish an AIDS cure research program under the Congressionally Directed Medical Research Program of the Department of Defense to support the discovery of a cure and new therapies for HIV/AIDS.
H.Res. 6187, The Cure for AIDS Act http://www.govtrack.us/congress/bills/112/hr6187 , introduced and referred to committee this July 25th, would fund research on new antiretrovirals, vaccine development, investigations into novel approaches to controlling viral diversity in highly restricted sanctuary regions and other means of addressing disease progression.
Dr. Robert Melamede, President and CEO of Cannabis Science stated, "Cannabis Science is very excited by the opportunity of this new program proposed by House Resolution 6187 to take further advantage of the momentum generated by AIDS 2012 and the consistent leadership of Representatives Lee and Himes in addressing the global AIDS crisis. This legislation serves to bring further attention to the immediate need of federal facilitation of new drug development to address the persistence of the AIDS pandemic on a global scale. New legislative initiatives such as the Cure for AIDS Act well help to move forward promising new therapeutics for HIV, such as our new CS-TATI-1 program, and potential cures. This bill encompasses support for both basic science and translational research in the pursuit of progress in treating HIV."
The U.S. government has historically facilitated HIV drug development through RO1 and SB1 grants and inclusion in the AIDS Clinical Trials Groups (ACTG), HIV Prevention Trails Network (HPTN), HIV Vaccine Trials Network (HVTN) or Military HIV Research Program (MHRP) federally funded research networks, which has led towards the development of 5 classes of antiretroviral therapy representing 20 HIV drugs.